Group items matching

in title, tags, annotations or url

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member.  The KOMP2 KO mouse phenotyping effort has generated 2,500 mouse strains with plans to generate an additional 6,000 over the next five years.  Overall, the IMPC hopes to achieve broad-based phenotyping of 20,000 KO strains.  About 30% of these strains either are or are expected to be embryonic or perinatal lethal or subviable.  A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes.  The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in depth phenotyping and research.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member.  The KOMP2 KO mouse phenotyping effort has generated 2,500 mouse strains with plans to generate an additional 6,000 over the next five years.  Overall, the IMPC hopes to achieve broad-based phenotyping of 20,000 KO strains.  About 30% of these strains either are or are expected to be embryonic or perinatal lethal or subviable.  A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes.  The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in depth phenotyping and research.

This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA.  An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required. Also listed under U44

NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material.

The U.S. Environmental Protection Agency (EPA) is seeking applications proposing to (1) identify communities that are at a high risk of experiencing the adverse health effects of lead in drinking water; (2) identify opportunities to mitigate these risks; and (3) conduct educational and outreach efforts so that water system managers and the general public are aware of these risks and opportunities.

The U.S. government's (USG) Global Health Security Agenda (GHSA) envisions a world safe and secure from global health threats posed by infectious diseases. The U.S. Centers for Disease Control and Prevention (CDC) is assisting the Governments globally to meet key International Health Regulations (IHR) (2005) requirements through the implementation of the GHSA. CDC seeks to partner with the Georgian Ministry of Agriculture, through a cooperative agreement in a collaborative effort to achieve specific goals in three focus areas of the GHSA specifically: 1. workforce capacity development through FELTP, 2. the "One Health" approach through coordination and collaboration, and 3. Laboratory system strengthening. The proposals funded through the cooperative agreement will respond to Zoonotic Disease Prevention of the GHSA by supporting the Georgian National Animal Health Plan, expanding and updating a cadre of the workforce and training of public health veterinarians to work with epidemiologists and laboratorians in the context of evidence-based timely detection and response, and adapting the One Health approach with the expected outcomes of stopping the diseases in animals before they spill-over into humans and strengthening the current surveillance system.

Through this BAA addendum, USAID seeks creation of a malaria evaluation and research partnership, via an organization or group of organization, to conduct future program evaluation and research activities, establish consensus for new collaborative research ideas, synthesize and conduct meta-analaysis of existing malaria data, and provide solutions to improve evaluation and research data utilization.

The Microsoft Foundation is inviting applications for its Dissertation Grants program. The program supports PhD students at North American universities who are underrepresented in the field of computing and pursuing research aligned to the research areas carried out by Microsoft Research. Through the program, recipients will receive funding of up to $25,000 for the 2020-21 academic year as well as an invitation to the PhD Summit, a two-day workshop in the fall held at one of Microsoft Research's labs where fellows will meet with Microsoft researchers and other top students to share their research. Fellows must be aligned in research areas as defined by Microsoft Research, which include artificial intelligence; audio and acoustics; computer vision; graphics and multimedia; human-computer interaction; human language technologies; search and information retrieval; data platforms and analytics; hardware and devices; programming languages and software engineering; security, privacy, and cryptography; systems and networking; algorithms; mathematics; ecology and environment; economics; medical, health, and genomics; social sciences; and technology for emerging markets.

One of the most important barriers to the provision and utilization of HIV prevention and care services is stigma, which is defined as an identity marked by disgrace, disapproval or shame, which often leads to discriminatory treatment by others. This RFA supports formative research to support development of stigma reduction interventions, as well as pilot or feasibility studies of new or adapted interventions to reduce stigma that impedes the provision and utilization of HIV care and prevention services.

This Funding Opportunity Announcement (FOA) seeks clinical research focused on the development and utilization of technologies that can help address patient outcomes. Relevant areas of technology include remote healthcare delivery to patients via telehealth, robotics to enhance medication adherence, on-site (e.g., clinical or home setting) care delivery, mobile heath to increase access and adherence, web-based decision support tools, and others. Research projects may focus on assessment, diagnosis, intervention development, or intervention implementation. Research projects that a) incorporate emerging and cutting edge technologies to explain and predict patient trajectories, b) inform interventions, c) support real-time clinical decision making, and d) facilitate effective long-term management of chronic illness are especially needed. Critical to this FOA, proposed research should identify specific patient outcomes expected to improve from technological approaches. The specific tools or interventions proposed should clearly indicate how they will enhance patient benefits in environments, such as clinical settings, and/or in the home and community. Also listed under R21

Studies of novel treatments include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years (Phase I; R21) for protocol development, target identification and studies to confirm target engagement (i.e., link targets with tangible outcomes); followed by up to 3 years of support (Phase II; R33) for replication studies of addiction treatment across 2 or more settings. Specifically, this latter phase will focus on clinical trials that apply the target in a treatment setting (development, refinement, and/or adaptation) to evaluate the feasibility of conducting a larger trial.

The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the usability and potential effectiveness of the IT-specific components of these new delivery models. Also listed under R01

The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications proposing research that will address behavioral, technical and practical aspects of interventions and communication strategies to reduce exposures and/or health risks of wildland fire smoke.

The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications proposing research that will address behavioral, technical and practical aspects of interventions and communication strategies to reduce exposures and/or health risks of wildland fire smoke.